KIT and hereditary clear cell renal cell carcinoma: Pieces of evidence such as the drug combination of sunitinib targeted PDGFRA and sorafenib targeted KIT, was proved to be successful for renal cell carcinoma in clinical trial phase 3 (Liu Y. et al., 2014).